Protalix BioTherapeutics, Inc.

PLX

$2.66

+1.34%

2026-09-04 12:07:25 EDT+$0.04

Healthcare

Biotechnology

AMEX

Active Trading

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant ...

Price Action of PLX

$2.66

+1.34%+$0.04

High—

Low—

52W High-16.6%

Rel. vol—

Interval

Range2.4h

Volume—SMA5SMA10

—

Protalix BioTherapeutics, Inc. (NYSE American, TASE: PLX) is an Israeli biopharmaceutical company established in 1993 and headquartered in Hackensack, New Jersey, with operations in Israel. The company's pioneering ProCellEx plant cell-based expression system enables the production of recombinant therapeutic proteins in engineered plant cells, making Protalix the first company to ...Protalix BioTherapeutics, Inc. (NYSE American, TASE: PLX) is an Israeli biopharmaceutical company established in 1993 and headquartered in Hackensack, New Jersey, with operations in Israel. The company's pioneering ProCellEx plant cell-based expression system enables the production of recombinant therapeutic proteins in engineered plant cells, making Protalix the first company to gain FDA approval for a plant-cell-produced protein. Their lead products include Elelyso (taliglucerase alfa) for Gaucher disease, approved in 2012 and marketed through partnerships, and Elfabrio (pegunigalsidase alfa) for Fabry disease, approved in 2023 in partnership with Chiesi. Additionally, the pipeline includes PRX-115, a PEGylated uricase for gout (Phase 2), and PRX-119 for NET-related diseases. Financially, Protalix has shown robust performance with a market cap of approximately $200M, revenue per share of $0.96, a gross profit margin of 70%, and positive net income margin of 20.1% (TTM). The company employs around 226 people and is led by CEO Dror Bashan, who has over 20 years of pharmaceutical experience, with co-founder Dr. Yoseph Shaaltiel contributing scientific leadership. Protalix maintains strategic collaborations with Pfizer (for Elelyso), Chiesi, Fundação Oswaldo Cruz, and Secarna Pharmaceuticals, and continues to innovate in plant-based protein manufacturing to address unmet medical needs in rare diseases.ExpandCollapse

Founded

1993

Employees

226

CEO

Dror Bashan

Full Name

Protalix BioTherapeutics, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

31.61%

Market Cap

$0.21B

Current Ratio

2.94

WACC

5.77%

ROIC

26.79%

Contact Information

https://www.protalix.com

201 696 9345

2 University Plaza, Hackensack, NJ 07601

Key Metrics of PLX

Snapshot

Latest / TTM · 6 periods

Market Cap

$213.92M

ROCE

29.5%

EV / EBITDA

7.34x

+39.4% YoY

FCF Yield

3.6%

+13.3% YoY

Cash Conversion Cycle

453.7d

Current Ratio

2.94

Quick take

TTM —

Positive CCC

Financial Highlights of PLX

Profitability trend

Latest / TTM · 6 periods

Gross Margin

69.2%

Net Margin

23.5%

P/E Ratio

10.87x

n/a

Debt / Equity

0.13

n/a

Current Ratio

2.94

Dividend Yield

0.0%

Understanding

TTM —

No major balance sheet stress in these headline ratios.

Calendar of PLX

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.02 · Revenue $13.37M · 1 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.01 · Revenue $16.10M · 1 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $0.22 · Revenue $79.79M · 1 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $0.01 · Revenue $16.10M · 1 analysts

Recent history

Aug 12, 2026
Q2 FY2026 · Results reported
EPS $0.05 · Revenue $19.90M
View filing
May 13, 2026
Q1 FY2026 · Results reported
EPS $0.22 · Revenue $33.75M
View filing
Mar 18, 2026
FY2025 · Annual results
EPS $-0.08 · Revenue $52.74M
View filing
Nov 13, 2025
Q3 FY2025 · Results reported
EPS $0.03 · Revenue $17.85M
View filing
Aug 14, 2025
Q2 FY2025 · Results reported
EPS $0.00 · Revenue $15.66M
View filing
May 9, 2025
Q1 FY2025 · Results reported
EPS $-0.05 · Revenue $10.11M
View filing

Financial Statements of PLX

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$52.7M	-1.2%	-41.0%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-6.6M	-325.2%	-79.4%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+47.8%	-12.1%	-30.5%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-10.4%	-242.2%	-62.5%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-12.5%	-328.0%	-65.0%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-13.6M	-284.4%	-151.7%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	-25.8%	-286.7%	-187.7%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	17.3%	+34.9%	+2.2%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	2.51x	+7.2%	-6.8%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$82.3M	+12.2%	+7.8%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-0.08 vs 0.03	-380.3%	0.05 vs -0.01	+600.0%
Revenue Surprise	$52.7M vs $62.0M	-14.9%	$19.9M vs $12.9M	+53.6%

Insider Transactions of PLX

Acquisitions (A)

Since Sep 3, 2026

Disposals (D)

Since Sep 3, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Sep 3, 2026	Naos Yaron	officer: Sr. VP & COO	Stock Option (Right to Buy)	A	112,000	$2.59
Sep 3, 2026	Naos Yaron	officer: Sr. VP & COO	Restricted Stock Units	A	56,000	—
Sep 3, 2026	Melincoff Gwen A	director	Stock Options (Right to Buy)	A	17,000	$2.59
Sep 3, 2026	Elze Christian	director	Stock Options (Right to Buy)	A	17,000	$2.59
Sep 3, 2026	Elze Christian	director	Restricted Stock Units	A	8,500	—

Earnings Call Transcript of PLX

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Second Quarter 2026 Financial and Business Results Conference Call. As a reminder, this conference is being recorded. I will now turn the conference over to your host, Mr. Mike Moyer of LifeSci Advisors, Investor Relations for Protalix. Please go ahead. Mike Moyer: Thank you, operator, and welcome to the Protalix BioTherapeutics Q2 2026 Financial Results and Business Update Conference Call. With me today are Dror Bashan, President and CEO; and Gilad Mamlok, Senior Vice President and Chief Financial Officer. Press release announcing the financial results and corporate updates was issued this morning and is available now on the Protalix website. Please take a moment to read the disclaimer about forward-looking statements in the press release. The earnings release and this teleconference include forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the statements made. Factors that could cause actual results to differ are described in the disclaimer and in Protalix' filings with the U.S. Securities and Exchange Commission. I will now turn the call over to Mr. Bashan. Dror? Dror Bashan: Thank you, Mike, and thank you, everyone, for joining this morning. Our results today reflect the strength of our profitable commercial partnerships, and we remain confident in our outlook for this year. We entered the second half of 2026 with Elfabrio sales through Chiesi continuing to drive growth of our business. Gilad will walk through the financial details, but the key driver in the first half was continued growth in Elfabrio's revenues, together with the previously reported $25 million Chiesi milestone payment recognized in the first quarter of this year. Elfabrio sales through Chiesi continue to drive revenues from selling, and this performance reflects further global penetration of Elfabrio and continued growth. This continued growth keeps us on track with our full year 2026 revenue guidance with the global Fabry market projected to reach approximately $3.2 billion by 2031, Elfabrio is positioned to capture 15% to 20% of this market, supported by our partnership with Chiesi, which is strengthened by the recent approval of the once every 4 weeks dosing regimen in Europe. We believe our revenue mix, particularly the continued expansion of Elfabrio position us well for sustained long-term value creation and [ profitability ]. On the clinical side, PRX-115 continues to advance as planned. PRX-115 is designed as a long-acting differentiated uricase, and we believe it has the potential to meaningfully improve quality of life for patients with uncontrolled gout, which could be a significant inflection point and revenue driver for Protalix. There is a significant unmet need in this population, and we expect top line results from our RELEASE study in the second …

Leadership Team of PLX

4 executives

Name	Title	Compensation	Gender	Year Born	Status
Dror Bashan	President, Chief Executive Officer & Director	USD 807,902	Male	1967	Active
Yaron Naos	SVP & COO	USD 418,139	Male	1964	Active
Gilad Mamlok	Senior VP, CFO Treasurer & Secretary	USD 309,415	Male	1968	Active
Yael Fellous	Vice President of Human Resources	—	Female	—	Active

Recent News of PLX

Seeking Alpha8/12/2026Neutral

Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript

PRNewsWire8/12/2026Neutral

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

Company to host conference call and webcast today at 8:00 a.m. EDT Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4 million from the second quarter of 2025, driven primarily by sales of Elfabrio® Total revenue climbed to $53.6 million, year to date, from $25.8 million for the same period in 2025, which includes the previously reported $25.0 million Chiesi milestone payment Year-to-date, the Company achieved profitability with a net income of $22.1 million The Company reiterates full-year 2026 guidance of $78.0 million to $83.0 million in total revenue PRX-115 Phase 2 study continues to advance as planned, with top-line results anticipated in the second half of 2027 Cash, cash equivalents, and short-term bank deposits were $40.7 million as of June 30, 2026, providing sufficient capital to fund ongoing operations including the Phase 2 RELEASE clinical trial of PRX-115 CARMIEL, Israel, Aug. 12, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the second quarter ended June 30, 2026, and provided a business and clinical update.

PRNewsWire8/5/2026Neutral

Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026

Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, Aug. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended June 30, 2026 and provide a business update on August 12, 2026.

Historical Employee Count of PLX

Current

226

Change

+9.18%

Minimum

193

Maximum

226

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	226	10-K	Mar 18, 2026	View
Dec 31, 2024	207	10-K	Mar 17, 2025	View
Dec 31, 2023	208	10-K	Mar 14, 2024	View
Dec 31, 2022	193	10-K	Feb 27, 2023	View
Dec 31, 2021	202	10-K	Mar 31, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Protalix BioTherapeutics, Inc.